Notably, a small molecule LRRK2 inhibitor, LRRK2-IN-1, demonstrated activity in colorectal and pancreatic cancer via direct inhibition of DCLK1 [64]; the clinical utility of such therapeutic agents could also spawn further from LRRK2-overexpressed cases. This evidence concerns the gene LRRK2 and pancreatic neoplasm.